Heidi Zhang

Heidi Zhang is the Chief Development Officer at Tune Therapeutics, where she leads global development of epigenetic precision medicines. She brings extensive experience in biologics and advanced therapy development, CMC strategy, and regulatory engagement, with prior leadership roles at Bristol Myers Squibb/Juno Therapeutics and Genentech. Heidi is an active leader in the CASSS community, including service on its Board of Directors and past involvement in the WCBP and CGTP conferences.